In addition, mTOR inhibition may have immunosuppressive effects that blunt an anti-GBM immune response, while DGKα inhibition should boost an anti-GBM immune response (to be addressed in more detail later in this review and elsewhere in this issue). This evidence concerns the gene DGKA and glioblastoma.